nodes	percent_of_prediction	percent_of_DWPC	metapath
Regorafenib—RAF1—lung cancer	0.0732	0.174	CbGaD
Regorafenib—FGFR1—lung cancer	0.072	0.171	CbGaD
Regorafenib—FLT1—lung cancer	0.0688	0.164	CbGaD
Regorafenib—BRAF—lung cancer	0.0507	0.121	CbGaD
Regorafenib—TEK—Crizotinib—lung cancer	0.0456	0.134	CbGbCtD
Regorafenib—EPHA2—Crizotinib—lung cancer	0.0456	0.134	CbGbCtD
Regorafenib—NTRK1—Crizotinib—lung cancer	0.0456	0.134	CbGbCtD
Regorafenib—KDR—lung cancer	0.0431	0.103	CbGaD
Regorafenib—KIT—lung cancer	0.0407	0.0968	CbGaD
Regorafenib—UGT1A1—lung cancer	0.0401	0.0953	CbGaD
Regorafenib—ABL1—Crizotinib—lung cancer	0.0226	0.0666	CbGbCtD
Regorafenib—ABCG2—lung cancer	0.0225	0.0536	CbGaD
Regorafenib—ABL1—Erlotinib—lung cancer	0.0218	0.0642	CbGbCtD
Regorafenib—UGT1A9—Irinotecan—lung cancer	0.01	0.0294	CbGbCtD
Regorafenib—ABCB1—lung cancer	0.00938	0.0223	CbGaD
Regorafenib—ABCG2—Topotecan—lung cancer	0.00921	0.0271	CbGbCtD
Regorafenib—UGT1A1—Erlotinib—lung cancer	0.00906	0.0267	CbGbCtD
Regorafenib—ABCG2—Gefitinib—lung cancer	0.00843	0.0248	CbGbCtD
Regorafenib—UGT1A1—Irinotecan—lung cancer	0.00818	0.0241	CbGbCtD
Regorafenib—ABCG2—Teniposide—lung cancer	0.00817	0.0241	CbGbCtD
Regorafenib—UGT1A1—Etoposide—lung cancer	0.00655	0.0193	CbGbCtD
Regorafenib—ABCG2—Erlotinib—lung cancer	0.00498	0.0147	CbGbCtD
Regorafenib—ABCG2—Paclitaxel—lung cancer	0.00456	0.0134	CbGbCtD
Regorafenib—ABCG2—Irinotecan—lung cancer	0.0045	0.0132	CbGbCtD
Regorafenib—CYP2C19—Gefitinib—lung cancer	0.00377	0.0111	CbGbCtD
Regorafenib—ABCG2—Cisplatin—lung cancer	0.00367	0.0108	CbGbCtD
Regorafenib—CYP2C19—Teniposide—lung cancer	0.00365	0.0107	CbGbCtD
Regorafenib—ABCG2—Etoposide—lung cancer	0.0036	0.0106	CbGbCtD
Regorafenib—ABCB1—Topotecan—lung cancer	0.00332	0.00978	CbGbCtD
Regorafenib—ABCG2—Docetaxel—lung cancer	0.0033	0.00971	CbGbCtD
Regorafenib—CYP2B6—Irinotecan—lung cancer	0.00316	0.00931	CbGbCtD
Regorafenib—CYP2C9—Gefitinib—lung cancer	0.00313	0.00922	CbGbCtD
Regorafenib—ABCB1—Gefitinib—lung cancer	0.00304	0.00894	CbGbCtD
Regorafenib—CYP2C9—Teniposide—lung cancer	0.00304	0.00894	CbGbCtD
Regorafenib—EPHA2—pulmonary artery—lung cancer	0.00285	0.0661	CbGeAlD
Regorafenib—CYP2C8—Erlotinib—lung cancer	0.00265	0.00781	CbGbCtD
Regorafenib—CYP2B6—Cisplatin—lung cancer	0.00258	0.00759	CbGbCtD
Regorafenib—ABCG2—Doxorubicin—lung cancer	0.00246	0.00724	CbGbCtD
Regorafenib—CYP2C8—Paclitaxel—lung cancer	0.00243	0.00715	CbGbCtD
Regorafenib—ABCG2—Methotrexate—lung cancer	0.00238	0.00701	CbGbCtD
Regorafenib—ABCB1—Vinorelbine—lung cancer	0.00234	0.00689	CbGbCtD
Regorafenib—CYP3A4—Topotecan—lung cancer	0.00199	0.00586	CbGbCtD
Regorafenib—CYP2C8—Etoposide—lung cancer	0.00192	0.00565	CbGbCtD
Regorafenib—ABCB1—Crizotinib—lung cancer	0.00186	0.00548	CbGbCtD
Regorafenib—CYP3A4—Gefitinib—lung cancer	0.00182	0.00536	CbGbCtD
Regorafenib—ABCB1—Gemcitabine—lung cancer	0.00182	0.00536	CbGbCtD
Regorafenib—ABCB1—Erlotinib—lung cancer	0.0018	0.00529	CbGbCtD
Regorafenib—FLT1—umbilical vein—lung cancer	0.00178	0.0412	CbGeAlD
Regorafenib—CYP3A4—Teniposide—lung cancer	0.00177	0.0052	CbGbCtD
Regorafenib—CYP2B6—Doxorubicin—lung cancer	0.00173	0.00509	CbGbCtD
Regorafenib—CYP2C9—Paclitaxel—lung cancer	0.00169	0.00499	CbGbCtD
Regorafenib—ABCB1—Paclitaxel—lung cancer	0.00164	0.00484	CbGbCtD
Regorafenib—ABCB1—Irinotecan—lung cancer	0.00162	0.00478	CbGbCtD
Regorafenib—KDR—umbilical vein—lung cancer	0.0015	0.0348	CbGeAlD
Regorafenib—ABCB1—Vinblastine—lung cancer	0.00144	0.00425	CbGbCtD
Regorafenib—DDR2—mammary gland—lung cancer	0.00143	0.0332	CbGeAlD
Regorafenib—CYP3A4—Vinorelbine—lung cancer	0.0014	0.00413	CbGbCtD
Regorafenib—CYP2C9—Cisplatin—lung cancer	0.00136	0.00401	CbGbCtD
Regorafenib—MAPK11—mammary gland—lung cancer	0.00136	0.0315	CbGeAlD
Regorafenib—ABCB1—Cisplatin—lung cancer	0.00132	0.00389	CbGbCtD
Regorafenib—ABCB1—Etoposide—lung cancer	0.0013	0.00382	CbGbCtD
Regorafenib—ABCB1—Docetaxel—lung cancer	0.00119	0.0035	CbGbCtD
Regorafenib—CYP3A4—Crizotinib—lung cancer	0.00112	0.00328	CbGbCtD
Regorafenib—CYP3A4—Erlotinib—lung cancer	0.00108	0.00317	CbGbCtD
Regorafenib—RAF1—Topotecan—Irinotecan—lung cancer	0.00102	0.593	CbGdCrCtD
Regorafenib—CYP3A4—Paclitaxel—lung cancer	0.000985	0.0029	CbGbCtD
Regorafenib—CYP3A4—Irinotecan—lung cancer	0.000972	0.00286	CbGbCtD
Regorafenib—EPHX2—mammary gland—lung cancer	0.000969	0.0224	CbGeAlD
Regorafenib—DDR2—respiratory system—lung cancer	0.000956	0.0221	CbGeAlD
Regorafenib—ABCB1—Doxorubicin—lung cancer	0.000886	0.00261	CbGbCtD
Regorafenib—CYP3A4—Vinblastine—lung cancer	0.000864	0.00254	CbGbCtD
Regorafenib—ABCB1—Methotrexate—lung cancer	0.000858	0.00253	CbGbCtD
Regorafenib—CYP3A4—Etoposide—lung cancer	0.000779	0.00229	CbGbCtD
Regorafenib—RET—mammary gland—lung cancer	0.000771	0.0179	CbGeAlD
Regorafenib—FGFR2—mammary gland—lung cancer	0.000733	0.017	CbGeAlD
Regorafenib—EPHA2—mammary gland—lung cancer	0.00072	0.0167	CbGeAlD
Regorafenib—CYP3A4—Docetaxel—lung cancer	0.000712	0.0021	CbGbCtD
Regorafenib—TEK—mammary gland—lung cancer	0.000702	0.0163	CbGeAlD
Regorafenib—PDGFRA—mammary gland—lung cancer	0.000636	0.0147	CbGeAlD
Regorafenib—Sorafenib—RAF1—lung cancer	0.000588	0.174	CrCbGaD
Regorafenib—FLT4—respiratory system—lung cancer	0.000582	0.0135	CbGeAlD
Regorafenib—Sorafenib—FGFR1—lung cancer	0.000579	0.171	CrCbGaD
Regorafenib—KDR—mammary gland—lung cancer	0.000574	0.0133	CbGeAlD
Regorafenib—Sorafenib—FLT1—lung cancer	0.000553	0.164	CrCbGaD
Regorafenib—CYP3A4—Doxorubicin—lung cancer	0.000531	0.00156	CbGbCtD
Regorafenib—KIT—mammary gland—lung cancer	0.000509	0.0118	CbGeAlD
Regorafenib—DDR2—lung—lung cancer	0.000507	0.0118	CbGeAlD
Regorafenib—PDGFRB—mammary gland—lung cancer	0.000497	0.0115	CbGeAlD
Regorafenib—FGFR2—respiratory system—lung cancer	0.000488	0.0113	CbGeAlD
Regorafenib—FLT4—epithelium—lung cancer	0.000486	0.0113	CbGeAlD
Regorafenib—EPHA2—respiratory system—lung cancer	0.00048	0.0111	CbGeAlD
Regorafenib—FGFR1—bronchus—lung cancer	0.000473	0.011	CbGeAlD
Regorafenib—TEK—respiratory system—lung cancer	0.000468	0.0108	CbGeAlD
Regorafenib—FLT1—respiratory system—lung cancer	0.000453	0.0105	CbGeAlD
Regorafenib—RAF1—respiratory system—lung cancer	0.00045	0.0104	CbGeAlD
Regorafenib—ABL1—mammary gland—lung cancer	0.000443	0.0103	CbGeAlD
Regorafenib—RET—epithelium—lung cancer	0.000429	0.00995	CbGeAlD
Regorafenib—PDGFRA—respiratory system—lung cancer	0.000424	0.00983	CbGeAlD
Regorafenib—ABL1—Topotecan—Irinotecan—lung cancer	0.000423	0.246	CbGdCrCtD
Regorafenib—FGFR2—epithelium—lung cancer	0.000408	0.00946	CbGeAlD
Regorafenib—Sorafenib—BRAF—lung cancer	0.000408	0.121	CrCbGaD
Regorafenib—EPHA2—epithelium—lung cancer	0.000401	0.00929	CbGeAlD
Regorafenib—FGFR1—cardiac atrium—lung cancer	0.000399	0.00924	CbGeAlD
Regorafenib—BRAF—bone marrow—lung cancer	0.000396	0.00917	CbGeAlD
Regorafenib—EPHA2—bronchus—lung cancer	0.000395	0.00915	CbGeAlD
Regorafenib—TEK—epithelium—lung cancer	0.000391	0.00906	CbGeAlD
Regorafenib—TEK—bronchus—lung cancer	0.000385	0.00893	CbGeAlD
Regorafenib—KDR—respiratory system—lung cancer	0.000383	0.00887	CbGeAlD
Regorafenib—FLT1—epithelium—lung cancer	0.000378	0.00876	CbGeAlD
Regorafenib—RAF1—epithelium—lung cancer	0.000376	0.00871	CbGeAlD
Regorafenib—FLT1—bronchus—lung cancer	0.000372	0.00863	CbGeAlD
Regorafenib—RAF1—bronchus—lung cancer	0.00037	0.00858	CbGeAlD
Regorafenib—BRAF—lung—lung cancer	0.000359	0.00831	CbGeAlD
Regorafenib—EPHA2—trachea—lung cancer	0.000355	0.00822	CbGeAlD
Regorafenib—DDR2—lymph node—lung cancer	0.000347	0.00804	CbGeAlD
Regorafenib—Sorafenib—KDR—lung cancer	0.000347	0.103	CrCbGaD
Regorafenib—EPHX2—lung—lung cancer	0.000343	0.00794	CbGeAlD
Regorafenib—FLT4—bone marrow—lung cancer	0.000341	0.00791	CbGeAlD
Regorafenib—KIT—respiratory system—lung cancer	0.000339	0.00786	CbGeAlD
Regorafenib—FLT1—trachea—lung cancer	0.000334	0.00775	CbGeAlD
Regorafenib—EPHA2—cardiac atrium—lung cancer	0.000333	0.00772	CbGeAlD
Regorafenib—RAF1—trachea—lung cancer	0.000333	0.0077	CbGeAlD
Regorafenib—PDGFRB—respiratory system—lung cancer	0.000331	0.00767	CbGeAlD
Regorafenib—MAPK11—lymph node—lung cancer	0.000329	0.00762	CbGeAlD
Regorafenib—Sorafenib—KIT—lung cancer	0.000327	0.0968	CrCbGaD
Regorafenib—TEK—cardiac atrium—lung cancer	0.000325	0.00753	CbGeAlD
Regorafenib—Sorafenib—UGT1A1—lung cancer	0.000322	0.0953	CrCbGaD
Regorafenib—KDR—epithelium—lung cancer	0.00032	0.00741	CbGeAlD
Regorafenib—KDR—bronchus—lung cancer	0.000315	0.0073	CbGeAlD
Regorafenib—FLT1—cardiac atrium—lung cancer	0.000314	0.00728	CbGeAlD
Regorafenib—PDGFRA—trachea—lung cancer	0.000313	0.00726	CbGeAlD
Regorafenib—RAF1—cardiac atrium—lung cancer	0.000312	0.00724	CbGeAlD
Regorafenib—FLT4—lung—lung cancer	0.000309	0.00716	CbGeAlD
Regorafenib—FGFR1—lung—lung cancer	0.000305	0.00707	CbGeAlD
Regorafenib—ABL1—respiratory system—lung cancer	0.000295	0.00684	CbGeAlD
Regorafenib—CYP2C8—mammary gland—lung cancer	0.000287	0.00666	CbGeAlD
Regorafenib—KIT—epithelium—lung cancer	0.000283	0.00657	CbGeAlD
Regorafenib—KDR—trachea—lung cancer	0.000283	0.00655	CbGeAlD
Regorafenib—KIT—bronchus—lung cancer	0.000279	0.00647	CbGeAlD
Regorafenib—PDGFRB—epithelium—lung cancer	0.000277	0.00641	CbGeAlD
Regorafenib—PDGFRB—bronchus—lung cancer	0.000273	0.00632	CbGeAlD
Regorafenib—KDR—cardiac atrium—lung cancer	0.000266	0.00615	CbGeAlD
Regorafenib—RAF1—bone marrow—lung cancer	0.000264	0.00611	CbGeAlD
Regorafenib—FGFR2—lung—lung cancer	0.000259	0.00601	CbGeAlD
Regorafenib—CYP2C9—mammary gland—lung cancer	0.000255	0.00591	CbGeAlD
Regorafenib—EPHA2—lung—lung cancer	0.000255	0.0059	CbGeAlD
Regorafenib—KIT—trachea—lung cancer	0.000251	0.00581	CbGeAlD
Regorafenib—TEK—lung—lung cancer	0.000249	0.00576	CbGeAlD
Regorafenib—BRAF—lymph node—lung cancer	0.000245	0.00568	CbGeAlD
Regorafenib—PDGFRB—trachea—lung cancer	0.000245	0.00567	CbGeAlD
Regorafenib—ABL1—bronchus—lung cancer	0.000243	0.00563	CbGeAlD
Regorafenib—FLT1—lung—lung cancer	0.00024	0.00557	CbGeAlD
Regorafenib—RAF1—lung—lung cancer	0.000239	0.00554	CbGeAlD
Regorafenib—EPHX2—lymph node—lung cancer	0.000234	0.00543	CbGeAlD
Regorafenib—PDGFRB—cardiac atrium—lung cancer	0.00023	0.00533	CbGeAlD
Regorafenib—PDGFRA—lung—lung cancer	0.000225	0.00522	CbGeAlD
Regorafenib—KDR—bone marrow—lung cancer	0.000224	0.0052	CbGeAlD
Regorafenib—ABL1—trachea—lung cancer	0.000218	0.00505	CbGeAlD
Regorafenib—FLT4—lymph node—lung cancer	0.000211	0.0049	CbGeAlD
Regorafenib—FGFR1—lymph node—lung cancer	0.000209	0.00483	CbGeAlD
Regorafenib—ABL1—cardiac atrium—lung cancer	0.000205	0.00475	CbGeAlD
Regorafenib—KDR—lung—lung cancer	0.000203	0.00471	CbGeAlD
Regorafenib—KIT—bone marrow—lung cancer	0.000199	0.0046	CbGeAlD
Regorafenib—PDGFRB—bone marrow—lung cancer	0.000194	0.0045	CbGeAlD
Regorafenib—RET—lymph node—lung cancer	0.000187	0.00432	CbGeAlD
Regorafenib—Sorafenib—ABCG2—lung cancer	0.000181	0.0536	CrCbGaD
Regorafenib—KIT—lung—lung cancer	0.00018	0.00417	CbGeAlD
Regorafenib—PDGFRB—lung—lung cancer	0.000176	0.00407	CbGeAlD
Regorafenib—EPHA2—lymph node—lung cancer	0.000174	0.00404	CbGeAlD
Regorafenib—ABL1—bone marrow—lung cancer	0.000173	0.00401	CbGeAlD
Regorafenib—CYP2B6—respiratory system—lung cancer	0.000172	0.00398	CbGeAlD
Regorafenib—TEK—lymph node—lung cancer	0.00017	0.00394	CbGeAlD
Regorafenib—FLT1—lymph node—lung cancer	0.000164	0.00381	CbGeAlD
Regorafenib—RAF1—lymph node—lung cancer	0.000163	0.00379	CbGeAlD
Regorafenib—ABL1—lung—lung cancer	0.000157	0.00363	CbGeAlD
Regorafenib—PDGFRA—lymph node—lung cancer	0.000154	0.00357	CbGeAlD
Regorafenib—CYP2B6—bronchus—lung cancer	0.000141	0.00327	CbGeAlD
Regorafenib—KDR—lymph node—lung cancer	0.000139	0.00322	CbGeAlD
Regorafenib—KIT—lymph node—lung cancer	0.000123	0.00285	CbGeAlD
Regorafenib—PDGFRB—lymph node—lung cancer	0.00012	0.00279	CbGeAlD
Regorafenib—ABCG2—bone marrow—lung cancer	0.000109	0.00253	CbGeAlD
Regorafenib—ABL1—lymph node—lung cancer	0.000107	0.00248	CbGeAlD
Regorafenib—ABCG2—lung—lung cancer	9.88e-05	0.00229	CbGeAlD
Regorafenib—ABL1—Idarubicin—Doxorubicin—lung cancer	9.19e-05	0.0536	CbGdCrCtD
Regorafenib—ABL1—Daunorubicin—Doxorubicin—lung cancer	9.19e-05	0.0536	CbGdCrCtD
Regorafenib—ABL1—Epirubicin—Doxorubicin—lung cancer	9.19e-05	0.0536	CbGdCrCtD
Regorafenib—ABCB1—respiratory system—lung cancer	9.18e-05	0.00213	CbGeAlD
Regorafenib—CYP2B6—lung—lung cancer	9.12e-05	0.00211	CbGeAlD
Regorafenib—ABCB1—epithelium—lung cancer	7.67e-05	0.00178	CbGeAlD
Regorafenib—Sorafenib—ABCB1—lung cancer	7.54e-05	0.0223	CrCbGaD
Regorafenib—ABCB1—trachea—lung cancer	6.78e-05	0.00157	CbGeAlD
Regorafenib—ABCG2—lymph node—lung cancer	6.76e-05	0.00157	CbGeAlD
Regorafenib—Pain—Vinorelbine—lung cancer	6.48e-05	0.000781	CcSEcCtD
Regorafenib—Alopecia—Etoposide—lung cancer	6.47e-05	0.000779	CcSEcCtD
Regorafenib—Mediastinal disorder—Paclitaxel—lung cancer	6.47e-05	0.000779	CcSEcCtD
Regorafenib—Hypertension—Gemcitabine—lung cancer	6.44e-05	0.000776	CcSEcCtD
Regorafenib—Anaemia—Cisplatin—lung cancer	6.43e-05	0.000774	CcSEcCtD
Regorafenib—Hepatobiliary disease—Docetaxel—lung cancer	6.41e-05	0.000772	CcSEcCtD
Regorafenib—Asthenia—Topotecan—lung cancer	6.36e-05	0.000766	CcSEcCtD
Regorafenib—Alopecia—Paclitaxel—lung cancer	6.34e-05	0.000764	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—lung cancer	6.31e-05	0.00076	CcSEcCtD
Regorafenib—Asthenia—Erlotinib—lung cancer	6.29e-05	0.000758	CcSEcCtD
Regorafenib—Malnutrition—Paclitaxel—lung cancer	6.25e-05	0.000753	CcSEcCtD
Regorafenib—Diarrhoea—Vinblastine—lung cancer	6.24e-05	0.000752	CcSEcCtD
Regorafenib—Leukopenia—Cisplatin—lung cancer	6.22e-05	0.00075	CcSEcCtD
Regorafenib—Infection—Irinotecan—lung cancer	6.21e-05	0.000748	CcSEcCtD
Regorafenib—Gastrointestinal pain—Vinorelbine—lung cancer	6.2e-05	0.000747	CcSEcCtD
Regorafenib—Nervous system disorder—Irinotecan—lung cancer	6.13e-05	0.000738	CcSEcCtD
Regorafenib—Thrombocytopenia—Irinotecan—lung cancer	6.12e-05	0.000737	CcSEcCtD
Regorafenib—Haemoglobin—Docetaxel—lung cancer	6.11e-05	0.000736	CcSEcCtD
Regorafenib—Haemorrhage—Docetaxel—lung cancer	6.08e-05	0.000733	CcSEcCtD
Regorafenib—Diarrhoea—Topotecan—lung cancer	6.06e-05	0.00073	CcSEcCtD
Regorafenib—Infection—Gemcitabine—lung cancer	6.05e-05	0.000729	CcSEcCtD
Regorafenib—Urinary tract disorder—Docetaxel—lung cancer	6.01e-05	0.000724	CcSEcCtD
Regorafenib—Diarrhoea—Erlotinib—lung cancer	6e-05	0.000723	CcSEcCtD
Regorafenib—Body temperature increased—Vinorelbine—lung cancer	5.99e-05	0.000722	CcSEcCtD
Regorafenib—Abdominal pain—Vinorelbine—lung cancer	5.99e-05	0.000722	CcSEcCtD
Regorafenib—Connective tissue disorder—Docetaxel—lung cancer	5.98e-05	0.00072	CcSEcCtD
Regorafenib—Nervous system disorder—Gemcitabine—lung cancer	5.97e-05	0.000719	CcSEcCtD
Regorafenib—Urethral disorder—Docetaxel—lung cancer	5.96e-05	0.000718	CcSEcCtD
Regorafenib—Thrombocytopenia—Gemcitabine—lung cancer	5.96e-05	0.000718	CcSEcCtD
Regorafenib—Skin disorder—Gemcitabine—lung cancer	5.91e-05	0.000713	CcSEcCtD
Regorafenib—Anaemia—Etoposide—lung cancer	5.89e-05	0.000709	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—lung cancer	5.88e-05	0.000708	CcSEcCtD
Regorafenib—Tremor—Paclitaxel—lung cancer	5.85e-05	0.000705	CcSEcCtD
Regorafenib—Vomiting—Vinblastine—lung cancer	5.8e-05	0.000699	CcSEcCtD
Regorafenib—Anaemia—Paclitaxel—lung cancer	5.77e-05	0.000696	CcSEcCtD
Regorafenib—Erythema multiforme—Docetaxel—lung cancer	5.75e-05	0.000693	CcSEcCtD
Regorafenib—Headache—Vinblastine—lung cancer	5.71e-05	0.000688	CcSEcCtD
Regorafenib—Toxic epidermal necrolysis—Methotrexate—lung cancer	5.71e-05	0.000687	CcSEcCtD
Regorafenib—Leukopenia—Etoposide—lung cancer	5.7e-05	0.000687	CcSEcCtD
Regorafenib—Cardiac disorder—Docetaxel—lung cancer	5.64e-05	0.00068	CcSEcCtD
Regorafenib—Infection—Cisplatin—lung cancer	5.64e-05	0.000679	CcSEcCtD
Regorafenib—Vomiting—Topotecan—lung cancer	5.63e-05	0.000679	CcSEcCtD
Regorafenib—Leukopenia—Paclitaxel—lung cancer	5.59e-05	0.000674	CcSEcCtD
Regorafenib—Rash—Topotecan—lung cancer	5.59e-05	0.000673	CcSEcCtD
Regorafenib—Dermatitis—Topotecan—lung cancer	5.58e-05	0.000672	CcSEcCtD
Regorafenib—Vomiting—Erlotinib—lung cancer	5.57e-05	0.000671	CcSEcCtD
Regorafenib—Nervous system disorder—Cisplatin—lung cancer	5.56e-05	0.000671	CcSEcCtD
Regorafenib—Thrombocytopenia—Cisplatin—lung cancer	5.56e-05	0.000669	CcSEcCtD
Regorafenib—Headache—Topotecan—lung cancer	5.55e-05	0.000669	CcSEcCtD
Regorafenib—Rash—Erlotinib—lung cancer	5.53e-05	0.000666	CcSEcCtD
Regorafenib—Dermatitis—Erlotinib—lung cancer	5.52e-05	0.000665	CcSEcCtD
Regorafenib—Angiopathy—Docetaxel—lung cancer	5.52e-05	0.000665	CcSEcCtD
Regorafenib—Skin disorder—Cisplatin—lung cancer	5.51e-05	0.000664	CcSEcCtD
Regorafenib—Hyponatraemia—Doxorubicin—lung cancer	5.51e-05	0.000664	CcSEcCtD
Regorafenib—Hypertension—Etoposide—lung cancer	5.5e-05	0.000663	CcSEcCtD
Regorafenib—Headache—Erlotinib—lung cancer	5.49e-05	0.000662	CcSEcCtD
Regorafenib—Mediastinal disorder—Docetaxel—lung cancer	5.48e-05	0.00066	CcSEcCtD
Regorafenib—Asthenia—Vinorelbine—lung cancer	5.44e-05	0.000655	CcSEcCtD
Regorafenib—Decreased appetite—Irinotecan—lung cancer	5.43e-05	0.000655	CcSEcCtD
Regorafenib—Nausea—Vinblastine—lung cancer	5.42e-05	0.000653	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Irinotecan—lung cancer	5.4e-05	0.00065	CcSEcCtD
Regorafenib—Hypertension—Paclitaxel—lung cancer	5.39e-05	0.00065	CcSEcCtD
Regorafenib—Fatigue—Irinotecan—lung cancer	5.39e-05	0.000649	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—lung cancer	5.39e-05	0.000649	CcSEcCtD
Regorafenib—ABCB1—bone marrow—lung cancer	5.38e-05	0.00125	CbGeAlD
Regorafenib—Alopecia—Docetaxel—lung cancer	5.37e-05	0.000647	CcSEcCtD
Regorafenib—Pain—Irinotecan—lung cancer	5.34e-05	0.000644	CcSEcCtD
Regorafenib—Malnutrition—Docetaxel—lung cancer	5.29e-05	0.000638	CcSEcCtD
Regorafenib—Decreased appetite—Gemcitabine—lung cancer	5.29e-05	0.000638	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—lung cancer	5.28e-05	0.000636	CcSEcCtD
Regorafenib—Nausea—Topotecan—lung cancer	5.26e-05	0.000634	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Gemcitabine—lung cancer	5.26e-05	0.000633	CcSEcCtD
Regorafenib—Fatigue—Gemcitabine—lung cancer	5.25e-05	0.000632	CcSEcCtD
Regorafenib—Pain—Gemcitabine—lung cancer	5.21e-05	0.000627	CcSEcCtD
Regorafenib—Nausea—Erlotinib—lung cancer	5.21e-05	0.000627	CcSEcCtD
Regorafenib—Dry mouth—Paclitaxel—lung cancer	5.2e-05	0.000627	CcSEcCtD
Regorafenib—Diarrhoea—Vinorelbine—lung cancer	5.18e-05	0.000625	CcSEcCtD
Regorafenib—Infection—Etoposide—lung cancer	5.16e-05	0.000622	CcSEcCtD
Regorafenib—Neutropenia—Methotrexate—lung cancer	5.12e-05	0.000617	CcSEcCtD
Regorafenib—Gastrointestinal pain—Irinotecan—lung cancer	5.11e-05	0.000616	CcSEcCtD
Regorafenib—Thrombocytopenia—Etoposide—lung cancer	5.09e-05	0.000613	CcSEcCtD
Regorafenib—Infection—Paclitaxel—lung cancer	5.06e-05	0.00061	CcSEcCtD
Regorafenib—Skin disorder—Etoposide—lung cancer	5.05e-05	0.000608	CcSEcCtD
Regorafenib—Dry skin—Doxorubicin—lung cancer	5.03e-05	0.000606	CcSEcCtD
Regorafenib—Nervous system disorder—Paclitaxel—lung cancer	5e-05	0.000602	CcSEcCtD
Regorafenib—Hypokalaemia—Doxorubicin—lung cancer	4.99e-05	0.000602	CcSEcCtD
Regorafenib—Thrombocytopenia—Paclitaxel—lung cancer	4.99e-05	0.000601	CcSEcCtD
Regorafenib—Skin disorder—Paclitaxel—lung cancer	4.95e-05	0.000597	CcSEcCtD
Regorafenib—Abdominal pain—Irinotecan—lung cancer	4.94e-05	0.000595	CcSEcCtD
Regorafenib—Body temperature increased—Irinotecan—lung cancer	4.94e-05	0.000595	CcSEcCtD
Regorafenib—Aspartate aminotransferase increased—Doxorubicin—lung cancer	4.94e-05	0.000595	CcSEcCtD
Regorafenib—Toxic epidermal necrolysis—Doxorubicin—lung cancer	4.94e-05	0.000595	CcSEcCtD
Regorafenib—Decreased appetite—Cisplatin—lung cancer	4.93e-05	0.000594	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Cisplatin—lung cancer	4.9e-05	0.00059	CcSEcCtD
Regorafenib—Anaemia—Docetaxel—lung cancer	4.89e-05	0.00059	CcSEcCtD
Regorafenib—Infestation—Methotrexate—lung cancer	4.88e-05	0.000588	CcSEcCtD
Regorafenib—Infestation NOS—Methotrexate—lung cancer	4.88e-05	0.000588	CcSEcCtD
Regorafenib—ABCB1—lung—lung cancer	4.87e-05	0.00113	CbGeAlD
Regorafenib—Pain—Cisplatin—lung cancer	4.85e-05	0.000585	CcSEcCtD
Regorafenib—Stevens-Johnson syndrome—Methotrexate—lung cancer	4.84e-05	0.000583	CcSEcCtD
Regorafenib—Alanine aminotransferase increased—Doxorubicin—lung cancer	4.84e-05	0.000583	CcSEcCtD
Regorafenib—Vomiting—Vinorelbine—lung cancer	4.82e-05	0.000581	CcSEcCtD
Regorafenib—Body temperature increased—Gemcitabine—lung cancer	4.81e-05	0.00058	CcSEcCtD
Regorafenib—Rash—Vinorelbine—lung cancer	4.78e-05	0.000576	CcSEcCtD
Regorafenib—Dermatitis—Vinorelbine—lung cancer	4.77e-05	0.000575	CcSEcCtD
Regorafenib—Stomatitis—Methotrexate—lung cancer	4.76e-05	0.000573	CcSEcCtD
Regorafenib—Headache—Vinorelbine—lung cancer	4.75e-05	0.000572	CcSEcCtD
Regorafenib—Leukopenia—Docetaxel—lung cancer	4.74e-05	0.000571	CcSEcCtD
Regorafenib—Hepatobiliary disease—Methotrexate—lung cancer	4.62e-05	0.000556	CcSEcCtD
Regorafenib—Hypertension—Docetaxel—lung cancer	4.57e-05	0.000551	CcSEcCtD
Regorafenib—Decreased appetite—Etoposide—lung cancer	4.52e-05	0.000545	CcSEcCtD
Regorafenib—Nausea—Vinorelbine—lung cancer	4.5e-05	0.000542	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Etoposide—lung cancer	4.49e-05	0.000541	CcSEcCtD
Regorafenib—Body temperature increased—Cisplatin—lung cancer	4.49e-05	0.00054	CcSEcCtD
Regorafenib—Asthenia—Irinotecan—lung cancer	4.48e-05	0.00054	CcSEcCtD
Regorafenib—Fatigue—Etoposide—lung cancer	4.48e-05	0.00054	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	4.48e-05	0.000539	CcSEcCtD
Regorafenib—Pain—Etoposide—lung cancer	4.45e-05	0.000536	CcSEcCtD
Regorafenib—Neutropenia—Doxorubicin—lung cancer	4.43e-05	0.000534	CcSEcCtD
Regorafenib—Decreased appetite—Paclitaxel—lung cancer	4.43e-05	0.000534	CcSEcCtD
Regorafenib—Dry mouth—Docetaxel—lung cancer	4.41e-05	0.000531	CcSEcCtD
Regorafenib—Haemoglobin—Methotrexate—lung cancer	4.41e-05	0.000531	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Paclitaxel—lung cancer	4.4e-05	0.00053	CcSEcCtD
Regorafenib—Fatigue—Paclitaxel—lung cancer	4.39e-05	0.000529	CcSEcCtD
Regorafenib—Haemorrhage—Methotrexate—lung cancer	4.38e-05	0.000528	CcSEcCtD
Regorafenib—Asthenia—Gemcitabine—lung cancer	4.37e-05	0.000526	CcSEcCtD
Regorafenib—Pain—Paclitaxel—lung cancer	4.36e-05	0.000525	CcSEcCtD
Regorafenib—Urinary tract disorder—Methotrexate—lung cancer	4.33e-05	0.000522	CcSEcCtD
Regorafenib—Urethral disorder—Methotrexate—lung cancer	4.3e-05	0.000518	CcSEcCtD
Regorafenib—Infection—Docetaxel—lung cancer	4.29e-05	0.000517	CcSEcCtD
Regorafenib—Weight decreased—Doxorubicin—lung cancer	4.29e-05	0.000517	CcSEcCtD
Regorafenib—Diarrhoea—Irinotecan—lung cancer	4.28e-05	0.000515	CcSEcCtD
Regorafenib—Gastrointestinal pain—Etoposide—lung cancer	4.25e-05	0.000512	CcSEcCtD
Regorafenib—Nervous system disorder—Docetaxel—lung cancer	4.24e-05	0.000511	CcSEcCtD
Regorafenib—Thrombocytopenia—Docetaxel—lung cancer	4.23e-05	0.00051	CcSEcCtD
Regorafenib—Infestation—Doxorubicin—lung cancer	4.23e-05	0.000509	CcSEcCtD
Regorafenib—Infestation NOS—Doxorubicin—lung cancer	4.23e-05	0.000509	CcSEcCtD
Regorafenib—Skin disorder—Docetaxel—lung cancer	4.2e-05	0.000506	CcSEcCtD
Regorafenib—Stevens-Johnson syndrome—Doxorubicin—lung cancer	4.19e-05	0.000505	CcSEcCtD
Regorafenib—Gastrointestinal pain—Paclitaxel—lung cancer	4.17e-05	0.000502	CcSEcCtD
Regorafenib—Diarrhoea—Gemcitabine—lung cancer	4.17e-05	0.000502	CcSEcCtD
Regorafenib—Erythema multiforme—Methotrexate—lung cancer	4.14e-05	0.000499	CcSEcCtD
Regorafenib—Stomatitis—Doxorubicin—lung cancer	4.12e-05	0.000497	CcSEcCtD
Regorafenib—Abdominal pain—Etoposide—lung cancer	4.11e-05	0.000495	CcSEcCtD
Regorafenib—Body temperature increased—Etoposide—lung cancer	4.11e-05	0.000495	CcSEcCtD
Regorafenib—Asthenia—Cisplatin—lung cancer	4.07e-05	0.000491	CcSEcCtD
Regorafenib—Cardiac disorder—Methotrexate—lung cancer	4.07e-05	0.00049	CcSEcCtD
Regorafenib—Abdominal pain—Paclitaxel—lung cancer	4.03e-05	0.000486	CcSEcCtD
Regorafenib—Body temperature increased—Paclitaxel—lung cancer	4.03e-05	0.000486	CcSEcCtD
Regorafenib—Hepatobiliary disease—Doxorubicin—lung cancer	4e-05	0.000482	CcSEcCtD
Regorafenib—Angiopathy—Methotrexate—lung cancer	3.98e-05	0.000479	CcSEcCtD
Regorafenib—Vomiting—Irinotecan—lung cancer	3.97e-05	0.000479	CcSEcCtD
Regorafenib—Mediastinal disorder—Methotrexate—lung cancer	3.95e-05	0.000476	CcSEcCtD
Regorafenib—Rash—Irinotecan—lung cancer	3.94e-05	0.000475	CcSEcCtD
Regorafenib—Dermatitis—Irinotecan—lung cancer	3.94e-05	0.000474	CcSEcCtD
Regorafenib—Headache—Irinotecan—lung cancer	3.92e-05	0.000472	CcSEcCtD
Regorafenib—Diarrhoea—Cisplatin—lung cancer	3.88e-05	0.000468	CcSEcCtD
Regorafenib—Alopecia—Methotrexate—lung cancer	3.87e-05	0.000467	CcSEcCtD
Regorafenib—Vomiting—Gemcitabine—lung cancer	3.87e-05	0.000466	CcSEcCtD
Regorafenib—Rash—Gemcitabine—lung cancer	3.84e-05	0.000463	CcSEcCtD
Regorafenib—Dermatitis—Gemcitabine—lung cancer	3.84e-05	0.000462	CcSEcCtD
Regorafenib—Malnutrition—Methotrexate—lung cancer	3.82e-05	0.00046	CcSEcCtD
Regorafenib—Haemoglobin—Doxorubicin—lung cancer	3.81e-05	0.00046	CcSEcCtD
Regorafenib—Headache—Gemcitabine—lung cancer	3.81e-05	0.00046	CcSEcCtD
Regorafenib—Haemorrhage—Doxorubicin—lung cancer	3.8e-05	0.000457	CcSEcCtD
Regorafenib—Decreased appetite—Docetaxel—lung cancer	3.76e-05	0.000453	CcSEcCtD
Regorafenib—Urinary tract disorder—Doxorubicin—lung cancer	3.75e-05	0.000452	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Docetaxel—lung cancer	3.73e-05	0.000449	CcSEcCtD
Regorafenib—Asthenia—Etoposide—lung cancer	3.73e-05	0.000449	CcSEcCtD
Regorafenib—Connective tissue disorder—Doxorubicin—lung cancer	3.73e-05	0.000449	CcSEcCtD
Regorafenib—Fatigue—Docetaxel—lung cancer	3.72e-05	0.000449	CcSEcCtD
Regorafenib—Urethral disorder—Doxorubicin—lung cancer	3.72e-05	0.000448	CcSEcCtD
Regorafenib—Nausea—Irinotecan—lung cancer	3.71e-05	0.000447	CcSEcCtD
Regorafenib—Pain—Docetaxel—lung cancer	3.69e-05	0.000445	CcSEcCtD
Regorafenib—Asthenia—Paclitaxel—lung cancer	3.66e-05	0.000441	CcSEcCtD
Regorafenib—Nausea—Gemcitabine—lung cancer	3.62e-05	0.000436	CcSEcCtD
Regorafenib—Vomiting—Cisplatin—lung cancer	3.61e-05	0.000435	CcSEcCtD
Regorafenib—Erythema multiforme—Doxorubicin—lung cancer	3.59e-05	0.000432	CcSEcCtD
Regorafenib—Rash—Cisplatin—lung cancer	3.58e-05	0.000431	CcSEcCtD
Regorafenib—Dermatitis—Cisplatin—lung cancer	3.57e-05	0.000431	CcSEcCtD
Regorafenib—Diarrhoea—Etoposide—lung cancer	3.56e-05	0.000429	CcSEcCtD
Regorafenib—Gastrointestinal pain—Docetaxel—lung cancer	3.53e-05	0.000426	CcSEcCtD
Regorafenib—Anaemia—Methotrexate—lung cancer	3.53e-05	0.000425	CcSEcCtD
Regorafenib—Cardiac disorder—Doxorubicin—lung cancer	3.52e-05	0.000424	CcSEcCtD
Regorafenib—Diarrhoea—Paclitaxel—lung cancer	3.49e-05	0.00042	CcSEcCtD
Regorafenib—Angiopathy—Doxorubicin—lung cancer	3.44e-05	0.000415	CcSEcCtD
Regorafenib—Mediastinal disorder—Doxorubicin—lung cancer	3.42e-05	0.000412	CcSEcCtD
Regorafenib—Body temperature increased—Docetaxel—lung cancer	3.42e-05	0.000412	CcSEcCtD
Regorafenib—Abdominal pain—Docetaxel—lung cancer	3.42e-05	0.000412	CcSEcCtD
Regorafenib—Leukopenia—Methotrexate—lung cancer	3.42e-05	0.000412	CcSEcCtD
Regorafenib—Nausea—Cisplatin—lung cancer	3.37e-05	0.000406	CcSEcCtD
Regorafenib—Alopecia—Doxorubicin—lung cancer	3.35e-05	0.000404	CcSEcCtD
Regorafenib—ABCB1—lymph node—lung cancer	3.33e-05	0.000772	CbGeAlD
Regorafenib—Vomiting—Etoposide—lung cancer	3.31e-05	0.000398	CcSEcCtD
Regorafenib—Malnutrition—Doxorubicin—lung cancer	3.3e-05	0.000398	CcSEcCtD
Regorafenib—Rash—Etoposide—lung cancer	3.28e-05	0.000395	CcSEcCtD
Regorafenib—Dermatitis—Etoposide—lung cancer	3.27e-05	0.000395	CcSEcCtD
Regorafenib—Headache—Etoposide—lung cancer	3.26e-05	0.000392	CcSEcCtD
Regorafenib—Vomiting—Paclitaxel—lung cancer	3.24e-05	0.00039	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	3.23e-05	0.000389	CcSEcCtD
Regorafenib—Rash—Paclitaxel—lung cancer	3.21e-05	0.000387	CcSEcCtD
Regorafenib—Dermatitis—Paclitaxel—lung cancer	3.21e-05	0.000387	CcSEcCtD
Regorafenib—Headache—Paclitaxel—lung cancer	3.19e-05	0.000385	CcSEcCtD
Regorafenib—Asthenia—Docetaxel—lung cancer	3.1e-05	0.000373	CcSEcCtD
Regorafenib—Infection—Methotrexate—lung cancer	3.09e-05	0.000373	CcSEcCtD
Regorafenib—Nausea—Etoposide—lung cancer	3.09e-05	0.000372	CcSEcCtD
Regorafenib—Nervous system disorder—Methotrexate—lung cancer	3.05e-05	0.000368	CcSEcCtD
Regorafenib—Anaemia—Doxorubicin—lung cancer	3.05e-05	0.000368	CcSEcCtD
Regorafenib—Thrombocytopenia—Methotrexate—lung cancer	3.05e-05	0.000367	CcSEcCtD
Regorafenib—Nausea—Paclitaxel—lung cancer	3.03e-05	0.000365	CcSEcCtD
Regorafenib—Skin disorder—Methotrexate—lung cancer	3.02e-05	0.000364	CcSEcCtD
Regorafenib—Leukopenia—Doxorubicin—lung cancer	2.96e-05	0.000356	CcSEcCtD
Regorafenib—Diarrhoea—Docetaxel—lung cancer	2.96e-05	0.000356	CcSEcCtD
Regorafenib—Hypertension—Doxorubicin—lung cancer	2.85e-05	0.000344	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	2.79e-05	0.000337	CcSEcCtD
Regorafenib—Dry mouth—Doxorubicin—lung cancer	2.75e-05	0.000331	CcSEcCtD
Regorafenib—Vomiting—Docetaxel—lung cancer	2.75e-05	0.000331	CcSEcCtD
Regorafenib—Rash—Docetaxel—lung cancer	2.72e-05	0.000328	CcSEcCtD
Regorafenib—Dermatitis—Docetaxel—lung cancer	2.72e-05	0.000328	CcSEcCtD
Regorafenib—Decreased appetite—Methotrexate—lung cancer	2.71e-05	0.000326	CcSEcCtD
Regorafenib—Headache—Docetaxel—lung cancer	2.71e-05	0.000326	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Methotrexate—lung cancer	2.69e-05	0.000324	CcSEcCtD
Regorafenib—Fatigue—Methotrexate—lung cancer	2.68e-05	0.000323	CcSEcCtD
Regorafenib—Infection—Doxorubicin—lung cancer	2.68e-05	0.000323	CcSEcCtD
Regorafenib—Pain—Methotrexate—lung cancer	2.66e-05	0.000321	CcSEcCtD
Regorafenib—Nervous system disorder—Doxorubicin—lung cancer	2.64e-05	0.000319	CcSEcCtD
Regorafenib—Thrombocytopenia—Doxorubicin—lung cancer	2.64e-05	0.000318	CcSEcCtD
Regorafenib—Skin disorder—Doxorubicin—lung cancer	2.62e-05	0.000316	CcSEcCtD
Regorafenib—Nausea—Docetaxel—lung cancer	2.57e-05	0.000309	CcSEcCtD
Regorafenib—Gastrointestinal pain—Methotrexate—lung cancer	2.55e-05	0.000307	CcSEcCtD
Regorafenib—Abdominal pain—Methotrexate—lung cancer	2.46e-05	0.000297	CcSEcCtD
Regorafenib—Body temperature increased—Methotrexate—lung cancer	2.46e-05	0.000297	CcSEcCtD
Regorafenib—Decreased appetite—Doxorubicin—lung cancer	2.34e-05	0.000282	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Doxorubicin—lung cancer	2.33e-05	0.00028	CcSEcCtD
Regorafenib—Fatigue—Doxorubicin—lung cancer	2.32e-05	0.00028	CcSEcCtD
Regorafenib—Pain—Doxorubicin—lung cancer	2.31e-05	0.000278	CcSEcCtD
Regorafenib—Asthenia—Methotrexate—lung cancer	2.23e-05	0.000269	CcSEcCtD
Regorafenib—Gastrointestinal pain—Doxorubicin—lung cancer	2.2e-05	0.000266	CcSEcCtD
Regorafenib—Body temperature increased—Doxorubicin—lung cancer	2.13e-05	0.000257	CcSEcCtD
Regorafenib—Abdominal pain—Doxorubicin—lung cancer	2.13e-05	0.000257	CcSEcCtD
Regorafenib—Diarrhoea—Methotrexate—lung cancer	2.13e-05	0.000257	CcSEcCtD
Regorafenib—Vomiting—Methotrexate—lung cancer	1.98e-05	0.000239	CcSEcCtD
Regorafenib—Rash—Methotrexate—lung cancer	1.96e-05	0.000237	CcSEcCtD
Regorafenib—Dermatitis—Methotrexate—lung cancer	1.96e-05	0.000236	CcSEcCtD
Regorafenib—Headache—Methotrexate—lung cancer	1.95e-05	0.000235	CcSEcCtD
Regorafenib—Asthenia—Doxorubicin—lung cancer	1.93e-05	0.000233	CcSEcCtD
Regorafenib—Nausea—Methotrexate—lung cancer	1.85e-05	0.000223	CcSEcCtD
Regorafenib—Diarrhoea—Doxorubicin—lung cancer	1.84e-05	0.000222	CcSEcCtD
Regorafenib—Vomiting—Doxorubicin—lung cancer	1.71e-05	0.000207	CcSEcCtD
Regorafenib—Rash—Doxorubicin—lung cancer	1.7e-05	0.000205	CcSEcCtD
Regorafenib—Dermatitis—Doxorubicin—lung cancer	1.7e-05	0.000205	CcSEcCtD
Regorafenib—Headache—Doxorubicin—lung cancer	1.69e-05	0.000204	CcSEcCtD
Regorafenib—Nausea—Doxorubicin—lung cancer	1.6e-05	0.000193	CcSEcCtD
Regorafenib—FGFR1—Disease—HRAS—lung cancer	5.68e-07	5.23e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CCND1—lung cancer	5.67e-07	5.23e-06	CbGpPWpGaD
Regorafenib—RAF1—Disease—EGFR—lung cancer	5.66e-07	5.22e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—HRAS—lung cancer	5.66e-07	5.22e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—TYMS—lung cancer	5.66e-07	5.22e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—JUN—lung cancer	5.66e-07	5.22e-06	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—TP53—lung cancer	5.65e-07	5.21e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—SRC—lung cancer	5.65e-07	5.21e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—MTOR—lung cancer	5.65e-07	5.21e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—PIK3CB—lung cancer	5.65e-07	5.21e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—SRC—lung cancer	5.64e-07	5.19e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PIK3CG—lung cancer	5.63e-07	5.19e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—GSTM1—lung cancer	5.6e-07	5.16e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—MAPK3—lung cancer	5.58e-07	5.15e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—HPGDS—lung cancer	5.58e-07	5.15e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—ENO2—lung cancer	5.58e-07	5.15e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PPP2R1B—lung cancer	5.55e-07	5.11e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—CAT—lung cancer	5.54e-07	5.1e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—HRAS—lung cancer	5.53e-07	5.09e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—PIK3CA—lung cancer	5.52e-07	5.08e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—MMP9—lung cancer	5.51e-07	5.08e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism of lipids and lipoproteins—EP300—lung cancer	5.51e-07	5.07e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—VEGFA—lung cancer	5.5e-07	5.07e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—VEGFA—lung cancer	5.49e-07	5.06e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CDKN1A—lung cancer	5.49e-07	5.06e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—MAPK3—lung cancer	5.49e-07	5.06e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—PTEN—lung cancer	5.47e-07	5.05e-06	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—IL6—lung cancer	5.47e-07	5.05e-06	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—KRAS—lung cancer	5.47e-07	5.04e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—STAT3—lung cancer	5.45e-07	5.02e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—CYP1A1—lung cancer	5.44e-07	5.01e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—NRAS—lung cancer	5.44e-07	5.01e-06	CbGpPWpGaD
Regorafenib—FGFR1—Disease—IL6—lung cancer	5.43e-07	5.01e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—STAT3—lung cancer	5.43e-07	5.01e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—MYC—lung cancer	5.43e-07	5.01e-06	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—AKT1—lung cancer	5.43e-07	5.01e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CXCL8—lung cancer	5.43e-07	5e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—NRAS—lung cancer	5.42e-07	5e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—IL6—lung cancer	5.42e-07	5e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—AKT1—lung cancer	5.42e-07	4.99e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—KRAS—lung cancer	5.42e-07	4.99e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—GSTT1—lung cancer	5.41e-07	4.99e-06	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—HRAS—lung cancer	5.4e-07	4.98e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—ERCC2—lung cancer	5.39e-07	4.97e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—HRAS—lung cancer	5.39e-07	4.97e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—ABCB1—lung cancer	5.39e-07	4.96e-06	CbGpPWpGaD
Regorafenib—ABL1—Immune System—HRAS—lung cancer	5.39e-07	4.96e-06	CbGpPWpGaD
Regorafenib—FGFR2—Disease—AKT1—lung cancer	5.38e-07	4.96e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—POMC—lung cancer	5.36e-07	4.94e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—GCLC—lung cancer	5.35e-07	4.93e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CYP2A6—lung cancer	5.35e-07	4.93e-06	CbGpPWpGaD
Regorafenib—RAF1—Disease—KRAS—lung cancer	5.35e-07	4.93e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—MYC—lung cancer	5.33e-07	4.92e-06	CbGpPWpGaD
Regorafenib—RAF1—Immune System—PIK3CA—lung cancer	5.32e-07	4.91e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—EGFR—lung cancer	5.31e-07	4.9e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—CYP1A1—lung cancer	5.31e-07	4.89e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—TYMS—lung cancer	5.29e-07	4.88e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—IL6—lung cancer	5.29e-07	4.88e-06	CbGpPWpGaD
Regorafenib—KIT—Disease—AKT1—lung cancer	5.28e-07	4.87e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—ERCC2—lung cancer	5.26e-07	4.85e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—GSTM1—lung cancer	5.23e-07	4.82e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—APOA1—lung cancer	5.23e-07	4.82e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—CREBBP—lung cancer	5.22e-07	4.82e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—EP300—lung cancer	5.22e-07	4.81e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—EGFR—lung cancer	5.22e-07	4.81e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—MAPK3—lung cancer	5.21e-07	4.8e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CASP3—lung cancer	5.19e-07	4.79e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—MAPK3—lung cancer	5.19e-07	4.79e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—IL2—lung cancer	5.19e-07	4.78e-06	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—IL6—lung cancer	5.17e-07	4.77e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—IL6—lung cancer	5.16e-07	4.76e-06	CbGpPWpGaD
Regorafenib—ABL1—Immune System—IL6—lung cancer	5.15e-07	4.75e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—HRAS—lung cancer	5.1e-07	4.7e-06	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—PTEN—lung cancer	5.09e-07	4.69e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—SRC—lung cancer	5.08e-07	4.68e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—ENO1—lung cancer	5.07e-07	4.68e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—MYC—lung cancer	5.06e-07	4.67e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CCND1—lung cancer	5.06e-07	4.66e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—MYC—lung cancer	5.05e-07	4.65e-06	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—AKT1—lung cancer	5.05e-07	4.65e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—JUN—lung cancer	5.04e-07	4.65e-06	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—PIK3CA—lung cancer	5.02e-07	4.63e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—KRAS—lung cancer	5.02e-07	4.63e-06	CbGpPWpGaD
Regorafenib—FGFR1—Disease—AKT1—lung cancer	5.01e-07	4.62e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	5e-07	4.61e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—AKT1—lung cancer	5e-07	4.61e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—PIK3CA—lung cancer	4.98e-07	4.59e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—CYP1A1—lung cancer	4.96e-07	4.57e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PIK3CD—lung cancer	4.95e-07	4.57e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—EGFR—lung cancer	4.95e-07	4.56e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—VEGFA—lung cancer	4.94e-07	4.56e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—EGFR—lung cancer	4.94e-07	4.55e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—KRAS—lung cancer	4.93e-07	4.54e-06	CbGpPWpGaD
Regorafenib—RAF1—Immune System—HRAS—lung cancer	4.93e-07	4.54e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—ERCC2—lung cancer	4.92e-07	4.53e-06	CbGpPWpGaD
Regorafenib—RAF1—Disease—PIK3CA—lung cancer	4.92e-07	4.53e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—MMP9—lung cancer	4.91e-07	4.52e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—STAT3—lung cancer	4.9e-07	4.51e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CDKN1A—lung cancer	4.89e-07	4.51e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—ALB—lung cancer	4.89e-07	4.51e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—NRAS—lung cancer	4.88e-07	4.5e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—IL6—lung cancer	4.88e-07	4.5e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—AKT1—lung cancer	4.88e-07	4.5e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—PTEN—lung cancer	4.88e-07	4.5e-06	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—TP53—lung cancer	4.86e-07	4.48e-06	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—EP300—lung cancer	4.85e-07	4.47e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—TP53—lung cancer	4.81e-07	4.44e-06	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—AKT1—lung cancer	4.77e-07	4.4e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PIK3CG—lung cancer	4.77e-07	4.4e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—AKT1—lung cancer	4.76e-07	4.39e-06	CbGpPWpGaD
Regorafenib—ABL1—Immune System—AKT1—lung cancer	4.76e-07	4.38e-06	CbGpPWpGaD
Regorafenib—RAF1—Immune System—IL6—lung cancer	4.71e-07	4.35e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—KRAS—lung cancer	4.68e-07	4.31e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—MAPK3—lung cancer	4.68e-07	4.31e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—KRAS—lung cancer	4.67e-07	4.3e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—APOA1—lung cancer	4.66e-07	4.3e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—EP300—lung cancer	4.65e-07	4.29e-06	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—HRAS—lung cancer	4.65e-07	4.28e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—PIK3CA—lung cancer	4.61e-07	4.25e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—HRAS—lung cancer	4.6e-07	4.24e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—APOA1—lung cancer	4.55e-07	4.2e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CYP2E1—lung cancer	4.55e-07	4.19e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—MYC—lung cancer	4.55e-07	4.19e-06	CbGpPWpGaD
Regorafenib—RAF1—Disease—HRAS—lung cancer	4.55e-07	4.19e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—POMC—lung cancer	4.54e-07	4.19e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—PIK3CA—lung cancer	4.53e-07	4.17e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—SRC—lung cancer	4.53e-07	4.17e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—AKT1—lung cancer	4.51e-07	4.15e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—NQO1—lung cancer	4.5e-07	4.15e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	4.47e-07	4.12e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—TP53—lung cancer	4.46e-07	4.11e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—EGFR—lung cancer	4.45e-07	4.1e-06	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—IL6—lung cancer	4.45e-07	4.1e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—CREBBP—lung cancer	4.42e-07	4.08e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—VEGFA—lung cancer	4.41e-07	4.06e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—IL6—lung cancer	4.41e-07	4.06e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—TP53—lung cancer	4.38e-07	4.04e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—STAT3—lung cancer	4.36e-07	4.02e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—NRAS—lung cancer	4.35e-07	4.01e-06	CbGpPWpGaD
Regorafenib—RAF1—Disease—IL6—lung cancer	4.35e-07	4.01e-06	CbGpPWpGaD
Regorafenib—RAF1—Immune System—AKT1—lung cancer	4.35e-07	4.01e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PIK3CB—lung cancer	4.32e-07	3.98e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—PIK3CA—lung cancer	4.3e-07	3.96e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—PIK3CA—lung cancer	4.29e-07	3.95e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PTGS2—lung cancer	4.28e-07	3.94e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—HRAS—lung cancer	4.27e-07	3.93e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PIK3CG—lung cancer	4.26e-07	3.93e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—APOA1—lung cancer	4.25e-07	3.92e-06	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—PIK3CA—lung cancer	4.23e-07	3.9e-06	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—PIK3CA—lung cancer	4.23e-07	3.9e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—KRAS—lung cancer	4.2e-07	3.87e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PIK3CD—lung cancer	4.19e-07	3.87e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—HRAS—lung cancer	4.19e-07	3.86e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—MAPK3—lung cancer	4.17e-07	3.84e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—TP53—lung cancer	4.16e-07	3.83e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PIK3CG—lung cancer	4.16e-07	3.83e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—TP53—lung cancer	4.15e-07	3.82e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—ALB—lung cancer	4.14e-07	3.82e-06	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—AKT1—lung cancer	4.1e-07	3.78e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—IL6—lung cancer	4.08e-07	3.76e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	4.07e-07	3.75e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—AKT1—lung cancer	4.06e-07	3.75e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—STK11—lung cancer	4.06e-07	3.74e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—MYC—lung cancer	4.05e-07	3.74e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—POMC—lung cancer	4.05e-07	3.74e-06	CbGpPWpGaD
Regorafenib—RAF1—Disease—AKT1—lung cancer	4.02e-07	3.7e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—IL6—lung cancer	4.01e-07	3.7e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—HRAS—lung cancer	3.98e-07	3.67e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—EGFR—lung cancer	3.97e-07	3.66e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—HRAS—lung cancer	3.97e-07	3.66e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—POMC—lung cancer	3.96e-07	3.65e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—CREBBP—lung cancer	3.95e-07	3.64e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PIK3CG—lung cancer	3.88e-07	3.58e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—PIK3CA—lung cancer	3.86e-07	3.56e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—CREBBP—lung cancer	3.85e-07	3.55e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—IL6—lung cancer	3.81e-07	3.51e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—IL6—lung cancer	3.8e-07	3.5e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—AKT1—lung cancer	3.77e-07	3.47e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—GSTP1—lung cancer	3.75e-07	3.46e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—KRAS—lung cancer	3.75e-07	3.45e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PIK3CD—lung cancer	3.74e-07	3.45e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—TP53—lung cancer	3.74e-07	3.44e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PTEN—lung cancer	3.73e-07	3.44e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—AKT1—lung cancer	3.7e-07	3.41e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—POMC—lung cancer	3.7e-07	3.41e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—ALB—lung cancer	3.7e-07	3.41e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PIK3CB—lung cancer	3.66e-07	3.37e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PIK3CD—lung cancer	3.65e-07	3.37e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CAT—lung cancer	3.65e-07	3.37e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PTGS2—lung cancer	3.62e-07	3.34e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—ALB—lung cancer	3.61e-07	3.32e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—CREBBP—lung cancer	3.6e-07	3.32e-06	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—PIK3CA—lung cancer	3.59e-07	3.31e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—HRAS—lung cancer	3.57e-07	3.29e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—EP300—lung cancer	3.56e-07	3.28e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—ABCB1—lung cancer	3.55e-07	3.27e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—AKT1—lung cancer	3.51e-07	3.24e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—AKT1—lung cancer	3.5e-07	3.23e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—TYMS—lung cancer	3.49e-07	3.22e-06	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—AKT1—lung cancer	3.46e-07	3.19e-06	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—AKT1—lung cancer	3.46e-07	3.19e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—GSTM1—lung cancer	3.45e-07	3.18e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—PIK3CA—lung cancer	3.44e-07	3.17e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—IL6—lung cancer	3.42e-07	3.15e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PIK3CD—lung cancer	3.41e-07	3.15e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—ALB—lung cancer	3.37e-07	3.11e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—TP53—lung cancer	3.33e-07	3.07e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CYP1A1—lung cancer	3.27e-07	3.01e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PIK3CB—lung cancer	3.26e-07	3.01e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—ERCC2—lung cancer	3.24e-07	2.99e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PTGS2—lung cancer	3.23e-07	2.98e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—HRAS—lung cancer	3.18e-07	2.94e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PIK3CB—lung cancer	3.18e-07	2.94e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PTEN—lung cancer	3.16e-07	2.91e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PTGS2—lung cancer	3.16e-07	2.91e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—AKT1—lung cancer	3.15e-07	2.91e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—IL6—lung cancer	3.05e-07	2.81e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—EP300—lung cancer	3.01e-07	2.78e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PIK3CB—lung cancer	2.98e-07	2.74e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PTGS2—lung cancer	2.95e-07	2.72e-06	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—AKT1—lung cancer	2.93e-07	2.7e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PTEN—lung cancer	2.82e-07	2.6e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—AKT1—lung cancer	2.81e-07	2.59e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—APOA1—lung cancer	2.8e-07	2.59e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PTEN—lung cancer	2.75e-07	2.54e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—EP300—lung cancer	2.69e-07	2.48e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PIK3CA—lung cancer	2.63e-07	2.43e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—EP300—lung cancer	2.62e-07	2.42e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PTEN—lung cancer	2.57e-07	2.37e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PIK3CG—lung cancer	2.56e-07	2.36e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—EP300—lung cancer	2.45e-07	2.26e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—POMC—lung cancer	2.44e-07	2.25e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CREBBP—lung cancer	2.37e-07	2.19e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PIK3CD—lung cancer	2.25e-07	2.07e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PIK3CA—lung cancer	2.23e-07	2.05e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—ALB—lung cancer	2.22e-07	2.05e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—AKT1—lung cancer	2.15e-07	1.98e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PIK3CA—lung cancer	1.99e-07	1.83e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PIK3CB—lung cancer	1.96e-07	1.81e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PTGS2—lung cancer	1.94e-07	1.79e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PIK3CA—lung cancer	1.94e-07	1.79e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—AKT1—lung cancer	1.82e-07	1.68e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PIK3CA—lung cancer	1.81e-07	1.67e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PTEN—lung cancer	1.7e-07	1.56e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—AKT1—lung cancer	1.62e-07	1.5e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—EP300—lung cancer	1.62e-07	1.49e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—AKT1—lung cancer	1.59e-07	1.46e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—AKT1—lung cancer	1.48e-07	1.37e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PIK3CA—lung cancer	1.2e-07	1.1e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—AKT1—lung cancer	9.77e-08	9.01e-07	CbGpPWpGaD
